- The CBL family of ubiquitin ligases—comprising c‑Cbl, Cbl‑b, and Cbl‑c—represents a highly conserved group of single‑chain RING finger E3 enzymes that play essential roles in regulating intracellular signalling. These proteins act as critical negative regulators of receptor tyrosine kinases (RTKs) and immune receptors, ensuring that signalling responses remain transient, balanced and tightly controlled. Although structurally similar, each CBL paralogue has evolved distinct biological functions, tissue expression patterns and regulatory mechanisms, making the family a central component of cellular homeostasis.
- All CBL proteins share a characteristic domain architecture. At the N‑terminus lies the TKB (tyrosine kinase‑binding) domain, a composite module consisting of a four‑helix bundle, an EF hand and an SH2‑like region. This domain enables CBL proteins to recognise and bind phosphorylated tyrosine residues on activated receptors or adaptor proteins. Adjacent to the TKB domain is the RING finger domain, a zinc‑binding module that interacts with ubiquitin‑charged E2 enzymes (E2~Ub). By correctly positioning the E2~Ub complex relative to the substrate, the RING domain catalyses direct ubiquitin transfer without forming a covalent E3~Ub intermediate. The C‑terminal regions of CBL proteins contain proline‑rich motifs and, in some paralogues, a ubiquitin‑associated (UBA) domain, which facilitate interactions with signalling adaptors and ubiquitin chains.
- Among the three paralogues, c‑Cbl is the most broadly expressed and extensively studied. It plays a central role in RTK downregulation, particularly targeting receptors such as EGFR, PDGFR, VEGFR and MET. Upon ligand stimulation, c‑Cbl binds phosphorylated receptors and catalyses their ubiquitination, promoting endocytosis and lysosomal degradation. This mechanism ensures that RTK signalling is rapidly attenuated, preventing excessive proliferative or inflammatory responses. Beyond RTKs, c‑Cbl regulates T‑cell receptor signalling, integrin pathways and innate immune responses. Mutations in c‑Cbl, especially those affecting the RING domain, have been linked to myeloid malignancies, where defective ubiquitination leads to prolonged kinase signalling and uncontrolled cell growth.
- In contrast, Cbl‑b is predominantly expressed in immune cells and functions as a key regulator of immune tolerance. It sets the activation threshold for T‑cells, B‑cells and NK cells by ubiquitinating signalling intermediates such as PI3K and PLC‑γ1. Loss of Cbl‑b results in hyperactive immune responses, autoimmunity and enhanced anti‑tumour immunity. Because of this, Cbl‑b has become a target of interest in cancer immunotherapy, where inhibiting Cbl‑b may amplify T‑cell activity against tumours. Its immune‑specific functions distinguish it sharply from c‑Cbl and Cbl‑c, highlighting the functional diversification within the CBL family.
- The third paralogue, Cbl‑c (also known as Cbl‑3), has a more restricted expression pattern, primarily in epithelial tissues. Structurally, Cbl‑c lacks some of the C‑terminal regulatory motifs found in c‑Cbl and Cbl‑b, limiting its adaptor interactions. Functionally, Cbl‑c regulates EGFR signalling and other epithelial RTKs, contributing to cell adhesion, differentiation and tissue homeostasis. Mutations or loss of Cbl‑c have been associated with epithelial cancers, including lung and colorectal carcinoma, where impaired RTK downregulation promotes oncogenic signalling. Although it shares catalytic features with c‑Cbl, its biological roles are more specialised and tissue‑specific.
- Mechanistically, all CBL proteins operate through non‑covalent catalysis. The RING domain binds the ubiquitin‑charged E2 enzyme and positions it correctly relative to the substrate, enabling direct transfer of ubiquitin to lysine residues or the N‑terminus of the target protein. Substrate specificity is determined by the TKB domain and additional motifs within each paralogue, allowing each CBL protein to recognise distinct signalling proteins. These ligases often assemble mono‑ubiquitin or K63‑linked chains, which serve as sorting signals for endocytosis and trafficking rather than proteasomal degradation.
- Biologically, the CBL family regulates essential processes including cell growth, immune activation, tissue homeostasis, inflammatory signalling and oncogenic suppression. Dysregulation of CBL proteins contributes to cancer, autoimmunity, chronic inflammation and immune deficiencies. Their central roles in signalling have made them attractive therapeutic targets, with c‑Cbl mutations informing kinase inhibitor strategies and Cbl‑b inhibition emerging as a promising approach in immuno‑oncology.
- In summary, the CBL family of ubiquitin ligases represents a versatile and evolutionarily conserved regulatory system that ensures balanced signalling across growth, immunity and tissue maintenance. Although c‑Cbl, Cbl‑b and Cbl‑c share a common structural framework, their distinct biological roles reflect the functional diversity required for precise control of cellular signalling. Understanding their mechanisms continues to provide valuable insights into disease pathogenesis and opportunities for targeted therapeutic intervention.
